Home Overview Press Room Blog Publications For Students about us
Search

Synthetic Biology : Displaying 37-46 of 270


The Scientific Swap Meet Behind the Gene-Editing Boomby Antonio RegaladoMIT Technology ReviewApril 8th, 2016A Cambridge non-profit called AddGene, described as "Amazon.com for biological parts," ships CRISPR-Cas9 parts all over the world.
CRISPR dispute raises bigger patent issues that we’re not talking aboutby Shobita ParthasarathyThe ConversationApril 4th, 2016CRISPR patents will confer enormous control over how the controversial technology develops, and what kinds of human genetic engineering might become commercially available.
Eugenics Revisited: Author Asks if We're Ready for Genetically Modified Humansby Howard LovyForeword ReviewsMarch 24th, 2016In an interview about his book GMO Sapiens: The Life-Changing Science of Designer Babies, Paul Knoepfler describes the intensifying debates over the creation of genetically modified human beings.
‘Minimal’ cell raises stakes in race to harness synthetic lifeby Ewen CallawayNature NewsMarch 24th, 2016Craig Venter’s latest creation comes as CRISPR gene-editing methods provide alternative ways to tinker with life’s building blocks.
Scientists develop new human stem cells with half a genomeby Bill BerkrotReutersMarch 16th, 2016Stem cells derived from a human egg are the first human cells known to be capable of division with just one copy of the parent cell's genome.
The Possibility Of A Three-Parent Baby[cites CGS' Marcy Darnovsky]by Indira LakshamananThe Diane Rehm ShowFebruary 25th, 2016A discussion about the science, ethics, and politics of a controversial technique that is a form of inheritable genetic modification.
What’s the difference between genetic engineering and eugenics?by Robert GebelhoffThe Washington PostFebruary 22nd, 2016Where we draw the line between "negative eugenics" and "positive genetic intervention" is a political question.
Who's Looking to Profit from Human Germline Changes?by Pete ShanksBiopolitical TimesJanuary 28th, 2016Billionaire Randal Kirk has assembled the components to commercialize heritable human genetic modification.
Why Is Editas Going Public? by Pete ShanksBiopolitical TimesJanuary 14th, 2016Editas, the gene-editing company founded by several of the scientists who developed CRISPR technology, announced on January 4th that it had filed preliminary paperwork for a public offering of stock.
Synthetic Biology's Defense Dollars: Signals and Perceptions by Dr. Filippa LentzosPLOS BlogsDecember 24th, 2015DARPA aims to develop radically new, game-changing technologies for national security and to create technological surprises for its enemies.
Displaying 37-46 of 270  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760